Safety, Pharmacokinetics, and Pharmacodynamics of the Insulin-Like Growth Factor Type 1 Receptor Inhibitor Figitumumab (CP-751,871) in Combination with Paclitaxel and Carboplatin

INTRODUCTION: This phase 1 study was conducted to determine the recommended phase 2 dose of the selective insulin-like growth factor type 1 receptor (IGF-IR) inhibitor figitumumab (F, CP-751,871) given in combination with paclitaxel and carboplatin in patients with advanced solid tumors. METHODS: Pa...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Karp, Daniel D., Pollak, Michael N., Cohen, Roger B., Eisenberg, Peter D., Haluska, Paul, Yin, Donghua, Lipton, Allan, Demers, Laurence, Leitzel, Kim, Hixon, Mary L., Terstappen, Leon W., Garland, Linda, Paz-Ares, Luis G., Cardenal, Felipe, Langer, Corey J., Gualberto, Antonio
Formato: Artigo
Lenguaje:Inglês
Publicado: 2009
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC2941876/
https://ncbi.nlm.nih.gov/pubmed/19745765
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/JTO.0b013e3181ba2f1d
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares